BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 26637849)

  • 1. Expression of PAX2 and PTEN Correlates to Therapy Response in Endometrial Hyperplasia.
    Ørbo A; Arnes M; Lyså LM; Straume B
    Anticancer Res; 2015 Dec; 35(12):6401-9. PubMed ID: 26637849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of Relapse After Therapy Withdrawal in Women with Endometrial Hyperplasia: A Long-term Follow-up Study.
    Sletten ET; Arnes M; Lysa LM; Moe BT; Straume B; Orbo A
    Anticancer Res; 2017 May; 37(5):2529-2536. PubMed ID: 28476823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulated progesterone receptor A and B coinciding with successful treatment of endometrial hyperplasia by the levonorgestrel impregnated intrauterine system.
    Orbo A; Arnes M; Pettersen I; Larsen K; Hanssen K; Moe B
    Acta Obstet Gynecol Scand; 2010 Nov; 89(11):1438-46. PubMed ID: 20955098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia.
    Vereide AB; Kaino T; Sager G; Arnes M; Ørbo A
    Gynecol Oncol; 2006 May; 101(2):214-23. PubMed ID: 16325240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levonorgestrel-releasing intrauterine system versus oral medroxyprogesterone acetate in infertile women with endometrial hyperplasia without atypia.
    Campo G; Rebecchi A; Vanni VS; Pagliardini L; Patruno C; Papaleo E; Candiani M; Giardina P
    Reprod Biomed Online; 2021 Nov; 43(5):864-870. PubMed ID: 34629315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of levonorgestrel-releasing intrauterine system versus oral progestins in treatment of simple endometrial hyperplasia without atypia.
    Ismail MT; Fahmy DM; Elshmaa NS
    Reprod Sci; 2013 Jan; 20(1):45-50. PubMed ID: 23203322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia--a long-term follow-up study.
    Varma R; Soneja H; Bhatia K; Ganesan R; Rollason T; Clark TJ; Gupta JK
    Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):169-75. PubMed ID: 18440693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens.
    Ørbo A; Arnes M; Vereide AB; Straume B
    BJOG; 2016 Aug; 123(9):1512-9. PubMed ID: 26630538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only.
    Ørbo A; Arnes M; Hancke C; Vereide AB; Pettersen I; Larsen K
    Gynecol Oncol; 2008 Oct; 111(1):68-73. PubMed ID: 18684496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial.
    Orbo A; Vereide A; Arnes M; Pettersen I; Straume B
    BJOG; 2014 Mar; 121(4):477-86. PubMed ID: 24286192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levonorgestrel-impregnated Intrauterine device reduces occurrence of hyperplastic polyps: a population-based follow-up cohort study.
    Arnes M; Hvingel B; Orbo A
    Anticancer Res; 2014 May; 34(5):2319-24. PubMed ID: 24778038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials.
    Abu Hashim H; Ghayaty E; El Rakhawy M
    Am J Obstet Gynecol; 2015 Oct; 213(4):469-78. PubMed ID: 25797236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis.
    Travaglino A; Raffone A; Saccone G; Insabato L; Mollo A; De Placido G; Zullo F
    Eur J Obstet Gynecol Reprod Biol; 2018 Dec; 231():104-110. PubMed ID: 30342311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific Biomarker Expression Patterns in the Diagnosis of Residual and Recurrent Endometrial Precancers After Progestin Treatment: A Longitudinal Study.
    Chen H; Lucas E; Strickland AL; Carrick K; Gwin K; Castrillon DH; Rivera-Colon G; Niu S; Molberg KH; Zheng W
    Am J Surg Pathol; 2020 Oct; 44(10):1429-1439. PubMed ID: 32931681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive ability of estrogen receptor (ER), progesterone receptor (PR), COX-2, Mlh1, and Bcl-2 expressions for regression and relapse of endometrial hyperplasia treated with LNG-IUS: a prospective cohort study.
    Gallos ID; Devey J; Ganesan R; Gupta JK
    Gynecol Oncol; 2013 Jul; 130(1):58-63. PubMed ID: 23603367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study.
    Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
    Hum Reprod; 2013 Nov; 28(11):2966-71. PubMed ID: 23975691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose LNG-IUS as Therapy for Endometrial Hyperplasia. A Prospective Cohort Pilot Study.
    Sletten ET; Arnes M; Vereide AB; Ørbo A
    Anticancer Res; 2018 May; 38(5):2883-2889. PubMed ID: 29715112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up.
    Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
    Hum Reprod; 2013 May; 28(5):1231-6. PubMed ID: 23466671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy: a comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone.
    Vereide AB; Kaino T; Sager G; Ørbo A;
    Gynecol Oncol; 2005 Jun; 97(3):740-50. PubMed ID: 15885761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer.
    Cholakian D; Hacker K; Fader AN; Gehrig PA; Tanner EJ
    Gynecol Oncol; 2016 Feb; 140(2):234-8. PubMed ID: 26706662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.